ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2022 Congress
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

Analysis of Hospitalization Factors of Hemophilia: 12 Years of Experience in a Single Center

C. Qu1, F. Xue1, W. Liu1, L. Chen1, L. Zhang1, R. Yang1

1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

Abstract Number: PO140

Meeting: ISTH 2021 Congress

Theme: Hemophilia and Rare Bleeding Disorders » Hemophilia - Clinical

Background: The hospital utilization and medical resource usage of hemophilia patients is closely related to the burden on China’s healthcare system.

Aims: This study was based on a single center in China and was conducted to comprehensively assess the hospitalization factors of hemophilia A or B patients.

Methods: We retrospectively analyzed clinical characteristics, diagnosis, inhibitor status, causes and duration of hospitalizations and medical costs of 323 hospitalizations in which hemophilia must be considered as the main cost factor during hospitalization from January 2009 to December 2020 from the Institute of Hematology and Blood Diseases Hospital in Tianjin, China. Non-parametric statistics were used and P<0.05 was considered statistically significant.

Results:

Severe hemophilia without inhibitor Moderate or mild hemophilia without inhibitor Inhibitor patients Total
Minor bleed 62 164 72 298
Major bleed 10 28 15 53
Pseudotumor 2 9 3 14
Surgery 0 9 1 10
Other 9 9 6 24
Total 83 219 97 399

Causes of hospitalizations
There were 265 hospitalizations with hemophilia A and 58 hospitalizations with hemophilia B. Seventy-eight hospitalizations were positive for inhibitor. Cause of most hospitalizations was minor bleeding (Table 1). The median length of hospitalization time was 5 (range 1~745) days. The cost of clotting factor concentrates is a major burden in the economic management of in-patients with hemophilia . Total cost in a single hospitalization of hemophilia A is about twice as much as hemophilia B. Expenditure of drugs in hemophilia A is two to three times more than that of hemophilia B. Total cost and drug cost in hospitalizations of patients with inhibitors were about two times more than these without. When normalized by weight, total cost of non-adults was significantly higher than adults (P=0.002). The positive rates were 1.8% for hepatitis B virus and 12.7% for hepatitis C virus in 283 hospitalizations screened for blood-borne infections.

Conclusions: For hemophilia, the main factor of cost during hospitalization is clotting factor concentrates. Diagnosed with hemophilia A and inhibitor positive increase the global cost.

To cite this abstract in AMA style:

Qu C, Xue F, Liu W, Chen L, Zhang L, Yang R. Analysis of Hospitalization Factors of Hemophilia: 12 Years of Experience in a Single Center [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 2). https://abstracts.isth.org/abstract/analysis-of-hospitalization-factors-of-hemophilia-12-years-of-experience-in-a-single-center/. Accessed September 29, 2023.

« Back to ISTH 2021 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/analysis-of-hospitalization-factors-of-hemophilia-12-years-of-experience-in-a-single-center/

Simple Search

Supported By:

Takeda logo

ISTH 2022 Congress site

Visit the official web site for the ISTH 2022 Virtual Congress »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2023 John Wiley & Sons, Inc. All Rights Reserved.
Wiley